Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62

Alsamman,Khaldoon; El‑Masry,Omar S.

doi:10.3892/or.2018.6615

Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62

Authors:
- Khaldoon Alsamman
- Omar S. El‑Masry
View Affiliations

Affiliations: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam 31441, Kingdom of Saudi Arabia, Department of Applied Medical Chemistry, Medical Research Institute, University of Alexandria, Alexandria 21561, Egypt
Published online on: August 1, 2018 https://doi.org/10.3892/or.2018.6615
Pages: 2157-2162

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer is one of the leading causes of mortality worldwide. Platinum‑based chemotherapeutic agents such as cisplatin are the first line of treatment for many types of cancers. However, the development of cisplatin resistance after prolonged treatment is a common cause of cancer recurrence. In the present study, we investigated an approach designed to overcome resistance to cisplatin involving co‑treatment with a second chemotherapeutic agent, staurosporine, and examined the role of sequestosome 1 (SQSTM1/p62) in enhancing cellular sensitivity to cisplatin. We utilized experimental models of three different cancers comprising cell lines derived from colon, breast, and ovarian tumors and investigated cell proliferation, morphology and p62 levels after treatment with cisplatin, staurosporine, or a combination of the two. Western blot analysis showed that cisplatin treatment resulted in elevation of p62 levels when compared to the corresponding control cells. Conversely, treatment with staurosporine resulted in a marked reduction in p62 levels in all three cell types and abrogated the cisplatin‑induced upregulation of p62. These results suggest that staurosporine could sensitize cancer cells to cisplatin via a mechanism involving downregulation of p62.

View Figures

View References

1	Ghoncheh M, Pournamdar Z and Salehiniya H: Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global patterns and trends in colorectal cancer incidence and mortality. Gut. 66:683–691. 2017. View Article : Google Scholar : PubMed/NCBI
4	Ai Z, Lu Y, Qiu S and Fan Z: Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett. 373:36–44. 2016. View Article : Google Scholar : PubMed/NCBI
5	Chen Y, Han F, Cao LH, Li C, Wang JW, Li Q, Zheng W, Guo ZX, Li AH and Zhou JH: Dose-response relationship in cisplatin-treated breast cancer xenografts monitored with dynamic contrast-enhanced ultrasound. BMC Cancer. 15:1362015. View Article : Google Scholar : PubMed/NCBI
6	Wahba HA and El-Hadaad HA: Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 12:106–116. 2015.PubMed/NCBI
7	Son DJ, Hong JE, Ban JO, Park JH, Lee HL, Gu SM, Hwang JY, Jung MH, Lee DW, Han SB and Hong JT: Synergistic inhibitory effects of cetuximab and cisplatin on human colon cancer cell growth via inhibition of the ERK-dependent EGF receptor signaling pathway. Biomed Res Int. 2015:3975632015. View Article : Google Scholar : PubMed/NCBI
8	Xia M, Yu H, Gu S, Xu Y, Su J, Li H, Kang J and Cui M: p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. Int J Oncol. 45:2341–2348. 2014. View Article : Google Scholar : PubMed/NCBI
9	Xue LY, Chiu SM and Oleinick NL: Staurosporine-induced death of MCF-7 human breast cancer cells: A distinction between caspase-3-dependent steps of apoptosis and the critical lethal lesions. Exp Cell Res. 283:135–145. 2003. View Article : Google Scholar : PubMed/NCBI
10	del Solar V, Lizardo DY, Li N, Hurst JJ, Brais CJ and Atilla-Gokcumen GE: Differential regulation of specific sphingolipids in colon cancer cells during staurosporine-induced apoptosis. Chem Biol. 22:1662–1670. 2015. View Article : Google Scholar : PubMed/NCBI
11	Manns J, Daubrawa M, Driessen S, Paasch F, Hoffmann N, Löffler A, Lauber K, Dieterle A, Alers S, Iftner T, et al: Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: Activation of caspase-9 in the absence of Apaf-1. FASEB J. 25:3250–3261. 2011. View Article : Google Scholar : PubMed/NCBI
12	Olguin-Albuerne M, Dominguez G and Morén J: Effect of staurosporine in the morphology and viability of cerebellar astrocytes: Role of reactive oxygen species and NADPH oxidase. Oxid Med Cell Longev. 2014:6783712014. View Article : Google Scholar : PubMed/NCBI
13	Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS and Doetsch PW: Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One. 8:e811622013. View Article : Google Scholar : PubMed/NCBI
14	Zhaleh H, Azadbakht M and Pour Bidmeshki A: Possible involvement of calcium channels and plasma membrane receptors on Staurosporine-induced neurite outgrowth. Bosn J Basic Med Sci. 12:20–25. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zhang XD, Gillespie SK and Hersey P: Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther. 3:187–197. 2004.PubMed/NCBI
16	Gil J, Almeida S, Oliveira CR and Rego AC: Cytosolic and mitochondrial ROS in staurosporine-induced retinal cell apoptosis. Free Radic Biol Med. 35:1500–1514. 2003. View Article : Google Scholar : PubMed/NCBI
17	Xiong Z, Fu Z, Shi J, Jiang X and Wan H: HtrA1 down-regulation induces cisplatin resistance in colon cancer by increasing XIAP and activating PI3K/Akt pathway. Ann Clin Lab Sci. 47:264–270. 2017.PubMed/NCBI
18	Cataldo A, Cheung DG, Balsari A, Tagliabue E, Coppola V, Iorio MV, Palmieri D and Croce CM: miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget. 7:786–797. 2016. View Article : Google Scholar : PubMed/NCBI
19	Chen J, Solomides C, Parekh H, Simpkins F and Simpkins H: Cisplatin resistance in human cervical, ovarian and lung cancer cells. Cancer Chemother Pharmacol. 75:1217–1227. 2015. View Article : Google Scholar : PubMed/NCBI
20	Eckstein N: Platinum resistance in breast and ovarian cancer cell lines. J Exp Clin Cancer Res. 30:912011. View Article : Google Scholar : PubMed/NCBI
21	Wang J and Wu GS: Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem. 289:17163–17173. 2014. View Article : Google Scholar : PubMed/NCBI
22	Aquino A, Prete SP, Baier S, Cappelletti D, Greiner JW, De Vecchis L, Graziani G and Bonmassar E: Staurosporine increases carcinoembryonic antigen expression in a human colon cancer cell line. J Chemother. 12:167–172. 2000. View Article : Google Scholar : PubMed/NCBI
23	Aquino A, Prete SP, Balduzzi A, Formica V, Fossile E, Bonmassar L, Concolino F, Bonmassar E and Graziani G: Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells. Int J Cancer. 100:119–121. 2002. View Article : Google Scholar : PubMed/NCBI
24	Yan XY, Zhang Y, Zhang JJ, Zhang LC, Liu YN, Wu Y, Xue YN, Lu SY, Su J and Sun LK: p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells. Cancer Sci. 108:1405–1413. 2017. View Article : Google Scholar : PubMed/NCBI
25	Brozovic A, Ambriovic-Ristov A and Osmak M: The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol. 40:347–359. 2010. View Article : Google Scholar : PubMed/NCBI